Scarica l'app Stockscreener
21.54
7.59%
1.52
Dopo l'orario di chiusura:
21.54
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$20.02
Aprire:
$20.41
Volume 24 ore:
1.33M
Relative Volume:
0.75
Capitalizzazione di mercato:
$1.90B
Reddito:
$203.45M
Utile/perdita netta:
$-351.45M
Rapporto P/E:
-4.7341
EPS:
-4.55
Flusso di cassa netto:
$-369.41M
1 W Prestazione:
+0.61%
1M Prestazione:
+48.55%
6M Prestazione:
+14.88%
1 anno Prestazione:
+241.90%
Intervallo 1D:
$20.40
$21.80
Intervallo di 1 settimana:
$19.65
$21.80
Portata 52W:
$6.01
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
Nome
Travere Therapeutics Inc
Settore
Industria
Telefono
888-969-7879
Indirizzo
3611 VALLEY CENTRE DR, SAN DIEGO
Confronta TVTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
21.54 | 1.90B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-09 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-03-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-12-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-20 | Iniziato | Citigroup | Neutral |
| 2023-09-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Ripresa | Evercore ISI | Outperform |
| 2023-07-21 | Iniziato | JP Morgan | Overweight |
| 2023-06-07 | Ripresa | Piper Sandler | Neutral |
| 2023-05-22 | Iniziato | TD Cowen | Outperform |
| 2023-05-05 | Aggiornamento | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-21 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-12-14 | Iniziato | Stifel | Hold |
| 2022-12-05 | Iniziato | Wells Fargo | Overweight |
| 2022-09-21 | Iniziato | Bryan Garnier | Sell |
| 2022-07-14 | Ripresa | Canaccord Genuity | Buy |
| 2022-03-31 | Iniziato | Piper Sandler | Overweight |
| 2022-02-28 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-26 | Downgrade | Wedbush | Outperform → Neutral |
Mostra tutto
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News - GuruFocus
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere, CSL gets standard EU approval for kidney disorder treatment - MSN
Travere Therapeutics to Participate at Upcoming Investor ConferencesMay 7, 2025 - BioSpace
Travere Therapeutics to Participate at Upcoming Investor Conferences | TVTX Stock News - GuruFocus
Homocystinuria Market Growth, Trends & Forecast 2025 | Leading - openPR.com
Travere therapeutics CEO sells $398k in stock By Investing.com - Investing.com Nigeria
Travere therapeutics CEO sells $398k in stock - Investing.com Australia
Travere therapeutics CFO sells shares worth $37,553 - Investing.com Australia
Travere therapeutics CFO sells shares worth $37,553 By Investing.com - Investing.com India
Travere Therapeutics Executives Sell Shares - TradingView
Travere Therapeutics anticipates FILSPARI approval for FSGS by September 2025 - MSN
(TVTX) Technical Data - news.stocktradersdaily.com
Analysts Have Made A Financial Statement On Travere Therapeutics, Inc.'s (NASDAQ:TVTX) First-Quarter Report - Yahoo
Travere Therapeutics (TVTX) Sees Promising Growth with FILSPARI - GuruFocus
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Travere Therapeutics Inc (TVTX): A Strategic SWOT Insig - GuruFocus
Travere Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Travere Therapeutics (TVTX) Rating and Price Target Update by We - GuruFocus
Travere Therapeutics (TVTX) Price Target Raised by Stifel | TVTX Stock News - GuruFocus
Travere Therapeutics Inc (TVTX) Q1 2025 Earnings Call Highlights: Robust Sales Growth Amidst ... - Yahoo
Travere Therapeutics Inc (TVTX) Q1 2025 Earnings Call Highlights: Robust Sales Growth Amidst Challenges - GuruFocus
Travere: Q1 Earnings Snapshot - Norwalk Hour
Travere Therapeutics Reports Strong Q1 2025 Financial Results - TipRanks
Travere Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Travere Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:TVTX) - Seeking Alpha
Earnings call transcript: Travere Therapeutics beats Q1 2025 EPS forecast By Investing.com - Investing.com South Africa
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Travere Therapeutics Reports First Quarter 2025 Financial Results - BioSpace
Earnings call transcript: Travere Therapeutics beats Q1 2025 EPS forecast - Investing.com
Travere Therapeutics (TVTX) Surpasses Revenue Expectations in Q1 - GuruFocus
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (TVTX) Travere Therapeutics Q1 Adjusted Loss Per Share $0.19 vs. FactSet Est Loss $0.36 - marketscreener.com
Travere Therapeutics, Inc. SEC 10-Q Report - TradingView
Travere Therapeutics (TVTX) Gains Standard EU Approval for Filsp - GuruFocus
European Commission Grants Standard Approval for Travere's Filsp - GuruFocus
Travere, CSL get standard EU nod for kidney drug (TVTX:NASDAQ) - Seeking Alpha
Travere, CSL Vifor Receive EU Marketing Approval for Filspari in IgA Nephropathy - marketscreener.com
Travere Therapeutics and CSL Vifor Announce Standard EU Approval - GuruFocus
Travere Therapeutics (TVTX) Gains Standard EU Approval for Filspari | TVTX Stock News - GuruFocus
How to interpret Travere Therapeutics Inc (TVTX)’s stock chart patterns - uspostnews.com
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy | TVTX Stock News - GuruFocus
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy - Business Wire
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy - The Manila Times
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy | CSLLY Stock News - GuruFocus
Cantor Fitzgerald maintains overweight on Travere Therapeutics stock By Investing.com - Investing.com Canada
Travere Therapeutics (TVTX) – Research Analysts’ Recent Ratings Updates - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Travere Therapeutics Inc Azioni (TVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):